MacroGenics, Inc.
MGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.71 | 0.09 | -0.12 |
| FCF Yield | -35.42% | -13.42% | -21.98% | -15.59% |
| EV / EBITDA | -1.01 | 262.16 | -3.13 | -4.53 |
| Quality | ||||
| ROIC | -51.01% | -68.37% | -50.32% | -75.10% |
| Gross Margin | 91.71% | 85.62% | 95.14% | 96.50% |
| Cash Conversion Ratio | 1.02 | 8.63 | 0.73 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.37% | -8.90% | 15.34% | 6.84% |
| Free Cash Flow Growth | 9.87% | 11.72% | 39.62% | -27.36% |
| Safety | ||||
| Net Debt / EBITDA | 2.53 | -33.21 | 0.69 | 0.51 |
| Interest Coverage | -99.17 | -117.65 | -461.67 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 6.73 | 5.09 | 0.60 |
| Cash Conversion Cycle | -138.17 | -165.66 | -35.38 | -1,479.83 |